RESUMO
Hyperthyroidism causes increased energy intake and expenditure, although anorexia and higher weight loss have been reported in elderly individuals with hyperthyroidism. To determine the effect of age on energy homeostasis in response to experimental hyperthyroidism, we administered 200 µg tri-iodothyronine (T3) in 7- and 27-mo-old rats for 14 d. T3 increased energy expenditure (EE) in both the young and the old rats, although the old rats lost more weight (147 g) than the young rats (58 g) because of the discordant effect of T3 on food intake, with a 40% increase in the young rats, but a 40% decrease in the old ones. The increased food intake in the young rats corresponded with a T3-mediated increase in the appetite-regulating proteins agouti-related peptide, neuropeptide Y, and uncoupling protein 2 in the hypothalamus, but no increase occurred in the old rats. Evidence of mitochondrial biogenesis in response to T3 was similar in the soleus muscle and heart of the young and old animals, but less consistent in old plantaris muscle and liver. Despite the comparable increase in EE, T3's effect on mitochondrial function was modulated by age in a tissue-specific manner. We conclude that older rats lack compensatory mechanisms to increase caloric intake in response to a T3-induced increase in EE, demonstrating a detrimental effect of age on energy homeostasis.
Assuntos
Fatores Etários , Metabolismo Energético , Homeostase , Hormônios Tireóideos/administração & dosagem , Animais , Citrato (si)-Sintase/genética , Citrato (si)-Sintase/metabolismo , DNA Mitocondrial/metabolismo , Ingestão de Alimentos , Hipertireoidismo/metabolismo , Hipotálamo/fisiologia , Masculino , RNA Mensageiro/genética , Ratos , Ratos Endogâmicos F344RESUMO
BACKGROUND: Glucocorticoids levels are high in catabolic conditions but it is unclear how much of the catabolic effects are due to negative energy balance versus glucocorticoids and whether there are distinct effects on metabolism and functions of specific muscle proteins. METHODOLOGY/PRINCIPAL FINDINGS: We determined whether 14 days of high dose methylprednisolone (MPred, 4 mg/kg/d) Vs food restriction (FR, food intake matched to MPred) in rats had different effects on muscle mitochondrial function and protein fractional synthesis rates (FSR). Lower weight loss (15%) occurred in FR than in MPred (30%) rats, while a 15% increase occurred saline-treated Controls. The per cent muscle loss was significantly greater for MPred than FR. Mitochondrial protein FSR in MPred rats was lower in soleus (51 and 43%, respectively) and plantaris (25 and 55%) than in FR, while similar decline in protein FSR of the mixed, sarcoplasmic, and myosin heavy chain occurred. Mitochondrial enzymatic activity and ATP production were unchanged in soleus while in plantaris cytochrome c oxidase activity was lower in FR than Control, and ATP production rate with pyruvate + malate in MPred plantaris was 28% lower in MPred. Branched-chain amino acid catabolic enzyme activities were higher in both FR and MPred rats indicating enhanced amino acid oxidation capacity. CONCLUSION/SIGNIFICANCE: MPred and FR had little impact on mitochondrial function but reduction in muscle protein synthesis occurred in MPred that could be explained on the basis of reduced food intake. A greater decline in proteolysis may explain lesser muscle loss in FR than in MPred rats.
Assuntos
Restrição Calórica , Metilprednisolona/administração & dosagem , Mitocôndrias Musculares/fisiologia , Proteínas Musculares/metabolismo , Músculo Esquelético/fisiologia , Trifosfato de Adenosina/biossíntese , Animais , Glicemia/análise , Peso Corporal , Relação Dose-Resposta a Droga , Insulina/sangue , Masculino , Ratos , Ratos Sprague-DawleyRESUMO
CONTEXT: Recent studies disputed the widely promoted anti-aging effect of dehydroepiandrosterone (DHEA) supplementation; however, conflicting data exist on whether physiological DHEA supplementation enhances exercise training effects on body composition, physical performance, and cardiometabolic risk in healthy postmenopausal women. OBJECTIVE: The aim of this study was to determine whether 12 wk of DHEA supplementation (50 mg/d) in postmenopausal women enhances exercise-related changes in body composition, physical performance, and cardiometabolic risk. DESIGN AND SETTING: This study was a 12-wk randomized double-blind, placebo-controlled trial and took place at the Mayo Clinic General Clinical Research Center (Rochester, MN). PARTICIPANTS: Thirty-one sedentary, postmenopausal, Caucasian women (mean +/- sem age 64.6 +/- 1.0 yr) completed the study. INTERVENTION: Participants were randomized to one of two 12-wk interventions: 1) exercise training plus 50 mg/d of DHEA (n = 17), or 2) exercise training plus placebo (n = 14). The exercise intervention consisted of both endurance (4 d/wk) and resistance (3 d/wk) exercise components. MAIN OUTCOME MEASURES: The main outcomes were measures of body composition, physical performance, and measures of cardiometabolic risk. RESULTS: DHEA treatment with exercise resulted in increases in circulating sulfated DHEA (650%), total testosterone (100%), estradiol (165%), estrone (85%), and IGF-I (30%) (all P < or = 0.05, for all within and between treatment comparisons). Although exercise training alone significantly improved physical performance, body composition, and insulin sensitivity, administration of DHEA provided no additional benefits. CONCLUSIONS: Twelve weeks of combined endurance and resistance training significantly improved body composition, physical performance, insulin sensitivity, and low-density lipoprotein cholesterol particle number and size, whereas DHEA had no additional benefits.
Assuntos
Desidroepiandrosterona/farmacologia , Resistência Física/efeitos dos fármacos , Aptidão Física/fisiologia , Pós-Menopausa/fisiologia , Idoso , Glicemia/metabolismo , Composição Corporal/efeitos dos fármacos , Composição Corporal/fisiologia , Colesterol/sangue , Desidroepiandrosterona/sangue , Sulfato de Desidroepiandrosterona/sangue , Método Duplo-Cego , Estradiol/sangue , Estrona/sangue , Feminino , Técnica Clamp de Glucose , Humanos , Resistência à Insulina/fisiologia , Fator de Crescimento Insulin-Like I/metabolismo , Pessoa de Meia-Idade , Resistência Física/fisiologia , Pós-Menopausa/sangue , Testosterona/sangue , Triglicerídeos/sangueRESUMO
BACKGROUND: Dehydroepiandrosterone (DHEA) and testosterone are widely promoted as antiaging supplements, but the long-term benefits, as compared with potential harm, are unknown. METHODS: We performed a 2-year, placebo-controlled, randomized, double-blind study involving 87 elderly men with low levels of the sulfated form of DHEA and bioavailable testosterone and 57 elderly women with low levels of sulfated DHEA. Among the men, 29 received DHEA, 27 received testosterone, and 31 received placebo. Among the women, 27 received DHEA and 30 received placebo. Outcome measures included physical performance, body composition, bone mineral density (BMD), glucose tolerance, and quality of life. RESULTS: As compared with the change from baseline to 24 months in the placebo group, subjects who received DHEA for 2 years had an increase in plasma levels of sulfated DHEA by a median of 3.4 microg per milliliter (9.2 micromol per liter) in men and by 3.8 microg per milliliter (10.3 micromol per liter) in women. Among men who received testosterone, the level of bioavailable testosterone increased by a median of 30.4 ng per deciliter (1.1 nmol per liter), as compared with the change in the placebo group. A separate analysis of men and women showed no significant effect of DHEA on body-composition measurements. Neither hormone altered the peak volume of oxygen consumed per minute, muscle strength, or insulin sensitivity. Men who received testosterone had a slight increase in fat-free mass, and men in both treatment groups had an increase in BMD at the femoral neck. Women who received DHEA had an increase in BMD at the ultradistal radius. Neither treatment improved the quality of life or had major adverse effects. CONCLUSIONS: Neither DHEA nor low-dose testosterone replacement in elderly people has physiologically relevant beneficial effects on body composition, physical performance, insulin sensitivity, or quality of life. (ClinicalTrials.gov number, NCT00254371 [ClinicalTrials.gov].).
Assuntos
Envelhecimento/efeitos dos fármacos , Composição Corporal/efeitos dos fármacos , Desidroepiandrosterona/administração & dosagem , Terapia de Reposição Hormonal , Aptidão Física , Testosterona/administração & dosagem , Adulto , Idoso , Densidade Óssea/efeitos dos fármacos , Desidroepiandrosterona/efeitos adversos , Desidroepiandrosterona/sangue , Método Duplo-Cego , Estradiol/sangue , Feminino , Terapia de Reposição Hormonal/efeitos adversos , Humanos , Resistência à Insulina , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Testosterona/efeitos adversos , Testosterona/sangue , Falha de TratamentoRESUMO
Amino acids (AAs), especially BCAAs, play pivotal roles in hormonal secretion and action as well as in intracellular signaling. There is emerging data showing that BCAAs regulate gene transcription and translation. Signaling proteins such as the mammalian target of rapamycin act as sensors of BCAAs, especially leucine, to modulate anabolic action. AAs stimulate protein synthesis and inhibit protein breakdown in skeletal muscle and liver. The specific role of BCAAs in regulating synthesis and breakdown of individual protein or proteins with common function or functions remains to be defined. Future studies should also focus on potential adverse effects of BCAAs on insulin sensitivity, renal function, and tumor growth. It also remains to be determined whether potential adverse effects of BCAA supplementation is similar in people of different age groups.
Assuntos
Aminoácidos de Cadeia Ramificada , Hormônios , Músculo Esquelético/metabolismo , Proteínas/metabolismo , Transdução de Sinais/fisiologia , Adulto , Aminoácidos de Cadeia Ramificada/metabolismo , Aminoácidos de Cadeia Ramificada/fisiologia , Glucose/metabolismo , Hormônios/metabolismo , Hormônios/fisiologia , Humanos , Masculino , Proteínas/fisiologia , Transdução de Sinais/efeitos dos fármacosRESUMO
Mitochondria are the primary site of skeletal muscle fuel metabolism and ATP production. Although insulin is a major regulator of fuel metabolism, its effect on mitochondrial ATP production is not known. Here we report increases in vastus lateralis muscle mitochondrial ATP production capacity (32-42%) in healthy humans (P < 0.01) i.v. infused with insulin (1.5 milliunits/kg of fat-free mass per min) while clamping glucose, amino acids, glucagon, and growth hormone. Increased ATP production occurred in association with increased mRNA levels from both mitochondrial (NADH dehydrogenase subunit IV) and nuclear [cytochrome c oxidase (COX) subunit IV] genes (164-180%) encoding mitochondrial proteins (P < 0.05). In addition, muscle mitochondrial protein synthesis, and COX and citrate synthase enzyme activities were increased by insulin (P < 0.05). Further studies demonstrated no effect of low to high insulin levels on muscle mitochondrial ATP production for people with type 2 diabetes mellitus, whereas matched nondiabetic controls increased 16-26% (P < 0.02) when four different substrate combinations were used. In conclusion, insulin stimulates mitochondrial oxidative phosphorylation in skeletal muscle along with synthesis of gene transcripts and mitochondrial protein in human subjects. Skeletal muscle of type 2 diabetic patients has a reduced capacity to increase ATP production with high insulin levels.